I agree with the comments by Rook and yourself regarding the current share count. Were that to be the position a year from now we'd justify a share price of $138.50 with significantly fewer sales.
But I wanted to err on the conservative side - and assumed by this time next year an additional eight million shares will have been issued.
Similarly I didn't mention sales for the treatment of routine TB infection.
If 5% of the estimated 12 million worldwide with active TB infection live in high-income countries, there are around 600,000 patients out there currently asked to endure six months of toxic therapy where a shorter regimen involving less toxicity will be an option.
was improved at the end of the on
phase of all 6 treatment
cycles with LAI
Patients who previously received LAI in CLEAR
108 appear to have
a sustained improvement in FEV
with longer term exposure
sputum density reductions were similar between patients
regardless of prior treatment assignment